Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder

Trial Profile

A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Autistic disorder; Bipolar I disorders; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2018 This trial has been completed in Hungary (end date: 2018-10-17)
    • 09 Oct 2018 Interim results (n=132) at 1 year assessing the effect of lurasidone on cognition in schizophrenic adolescents, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top